SMT202500237T1 - Forme cristalline di modulatore di p2x3 metil (s)-2-((2-(2,6-difluoro-4-(metilcarbamoil)fenil)-7-metilimidazo[1,2-a]piridin-3-il)metil)morfolina-4-carbossilato - Google Patents

Forme cristalline di modulatore di p2x3 metil (s)-2-((2-(2,6-difluoro-4-(metilcarbamoil)fenil)-7-metilimidazo[1,2-a]piridin-3-il)metil)morfolina-4-carbossilato

Info

Publication number
SMT202500237T1
SMT202500237T1 SM20250237T SMT202500237T SMT202500237T1 SM T202500237 T1 SMT202500237 T1 SM T202500237T1 SM 20250237 T SM20250237 T SM 20250237T SM T202500237 T SMT202500237 T SM T202500237T SM T202500237 T1 SMT202500237 T1 SM T202500237T1
Authority
SM
San Marino
Prior art keywords
methyl
methylimidazo
methylcarbamoyl
difluoro
pyridin
Prior art date
Application number
SM20250237T
Other languages
English (en)
Italian (it)
Inventor
Denis Garceau
Robert M Wenslow
Kemal Payza
Nathalie Chauret
Original Assignee
Glaxosmithkline Intellectual Property No 3 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property No 3 Ltd filed Critical Glaxosmithkline Intellectual Property No 3 Ltd
Publication of SMT202500237T1 publication Critical patent/SMT202500237T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
SM20250237T 2018-11-13 2019-11-12 Forme cristalline di modulatore di p2x3 metil (s)-2-((2-(2,6-difluoro-4-(metilcarbamoil)fenil)-7-metilimidazo[1,2-a]piridin-3-il)metil)morfolina-4-carbossilato SMT202500237T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862760307P 2018-11-13 2018-11-13
EP19884611.5A EP3880678B1 (en) 2018-11-13 2019-11-12 Crystalline forms of p2x3 modulator methyl (s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate
PCT/IB2019/001199 WO2020099923A1 (en) 2018-11-13 2019-11-12 Crystalline forms of a substituted imidazopyridine compound and use thereof as p2x3 modulator

Publications (1)

Publication Number Publication Date
SMT202500237T1 true SMT202500237T1 (it) 2025-07-22

Family

ID=70732059

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20250237T SMT202500237T1 (it) 2018-11-13 2019-11-12 Forme cristalline di modulatore di p2x3 metil (s)-2-((2-(2,6-difluoro-4-(metilcarbamoil)fenil)-7-metilimidazo[1,2-a]piridin-3-il)metil)morfolina-4-carbossilato

Country Status (20)

Country Link
US (1) US20220002292A1 (https=)
EP (1) EP3880678B1 (https=)
JP (2) JP2022507251A (https=)
CN (1) CN113302191A (https=)
AU (1) AU2019378161B2 (https=)
CA (1) CA3119711A1 (https=)
DK (1) DK3880678T3 (https=)
ES (1) ES3033466T3 (https=)
FI (1) FI3880678T3 (https=)
HR (1) HRP20250864T1 (https=)
HU (1) HUE071480T2 (https=)
IL (1) IL282996A (https=)
LT (1) LT3880678T (https=)
MX (1) MX2021005424A (https=)
PL (1) PL3880678T3 (https=)
PT (1) PT3880678T (https=)
RS (1) RS66922B1 (https=)
SI (1) SI3880678T1 (https=)
SM (1) SMT202500237T1 (https=)
WO (1) WO2020099923A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282087B2 (en) * 2018-10-10 2025-11-01 Bellus Health Cough Inc 4-(imidazo[1,2-a]pyridin-3-yl)-benzamide derivatives for treating pruritus
JP7578602B2 (ja) * 2019-02-25 2024-11-06 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー3)、リミテッド P2x3修飾薬での治療
CN114085220B (zh) * 2020-06-22 2023-06-16 上海海雁医药科技有限公司 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途
EP4169921A4 (en) * 2020-06-29 2024-06-19 Wuhan LL Science and Technology Development Co., Ltd. Crystalline form of heterocyclic compound, preparation method therefor and application thereof
WO2022161462A1 (zh) * 2021-01-29 2022-08-04 上海海雁医药科技有限公司 吗啉衍生物及其药物组合物和用途
WO2025140586A1 (zh) * 2023-12-29 2025-07-03 人福医药集团股份公司 一种p2x3受体拮抗剂的固体分散体及其制备工艺
WO2025191081A1 (en) 2024-03-15 2025-09-18 Glaxosmithkline Intellectual Property (No.3) Limited Crystalline form of camlipixant
WO2025210540A1 (en) 2024-04-02 2025-10-09 Assia Chemical Industries Ltd. Solid state forms of camlipixant and process for preparation thereof
WO2026022326A1 (en) * 2024-07-25 2026-01-29 Glaxosmithkline Intellectual Property (No.3) Limited P2x3 antagonist formulation
JP2026049185A (ja) 2024-09-06 2026-03-18 キヤノン株式会社 撮像装置、撮像方法、及びコンピュータプログラム

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3381917T3 (da) * 2013-01-31 2021-10-18 Bellus Health Cough Inc Imidazopyridinforbindelser og anvendelser deraf
US10111883B1 (en) 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators

Also Published As

Publication number Publication date
PT3880678T (pt) 2025-05-22
MX2021005424A (es) 2021-06-15
EP3880678A1 (en) 2021-09-22
CN113302191A (zh) 2021-08-24
JP2022507251A (ja) 2022-01-18
AU2019378161A1 (en) 2021-06-03
SI3880678T1 (sl) 2025-08-29
EP3880678A4 (en) 2022-08-31
AU2019378161B2 (en) 2025-01-30
LT3880678T (lt) 2025-06-25
HRP20250864T1 (hr) 2025-09-26
EP3880678B1 (en) 2025-05-07
HUE071480T2 (hu) 2025-08-28
RS66922B1 (sr) 2025-07-31
WO2020099923A1 (en) 2020-05-22
FI3880678T3 (fi) 2025-08-01
IL282996A (en) 2021-06-30
US20220002292A1 (en) 2022-01-06
PL3880678T3 (pl) 2025-08-04
DK3880678T3 (da) 2025-06-10
JP2024153665A (ja) 2024-10-29
CA3119711A1 (en) 2020-05-22
ES3033466T3 (en) 2025-08-04

Similar Documents

Publication Publication Date Title
PL3880678T3 (pl) Postacie krystaliczne modulatora p2x3: (s)-2-((2-(2,6-difluoro-4- (metylokarbamoilo)fenylo)-7-metyloimidazo[1,2-a]pirydyn-3-ylo)metylo)morfolino-4-karboksylanu metylu
IL280182A (en) Pyridin-2-one compounds useful as SMARCA2 antagonists
PL3784285T3 (pl) Środki krioprotekcyjne do formulacji cząstek stałych
IL289456A (en) Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds
IL271399A (en) Methods for the preparation of heterocyclic 3,1-benzodioxole compounds
IL254132B (en) A solid preparation of N-(4-(1(2,6-difluorobenzyl)-5-))dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxy-1,2,3 4-tetrahydrothiano[2,3-d]pyrimidine-6-yl)phenyl)-n-methoxyurea or its salt
EP3735243A4 (en) ISOTOPOLOGISTS OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE
IL259617B (en) Methods for the preparation of 3,1-benzodioxole heterocyclic compounds
ZA202110352B (en) New heterocyclic compounds
IL285721A (en) Methods of making high enantioselective secondary alcohols
IL276483A (en) A continuous process for the preparation of trazodone
PL3914558T3 (pl) Sposób przygotowania tytanianu bizmutowo-sodowego
HUE055530T2 (hu) 7H-pirrolo[2,3-D]pirimidin vegyület kristály formája és só formája, és ezek elkészítési eljárása
ZA202000224B (en) 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride polymorph, preparation method therefor and application thereof
EP4021361A4 (en) ADVANCED TOOLS FOR IMPLANTATION OF BONE CONDUITS
HUE063815T2 (hu) Eljárás faszén elõállítására
CO2017009662A2 (es) Formas cristalinas de un compuesto de pirrolopiridina
JP1715521S (ja) フライパン用柄
IL287228A (en) A process for producing modified 2-[2-(phenyl)ethylamino]alkanamide derivatives
MX375758B (es) Sales y polimorfos de un compuesto imidazopiridinil-aminopiridina sustituido.
SG11201701674RA (en) Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
PL3643704T3 (pl) Nowe produkty pośrednie do wytwarzania chlorowodorku remifentanilu
EP3421474A4 (en) NEW CRYSTALLINE FORMS OF (6- (1H-INDAZOLE-6-YL) -N- [4- (4-MORPHOLINYL) PHENYL] IMIDAZO [1,2-A] PYRAZIN-8-AMINE) -METHANESULFONATE
IL278946A (en) A method for heat transfer across a rotary joint
IL286545A (en) Food preparation robot and method for use